Back
Full-text
Journal article

Ideal Cardiovascular Health and Subclinical Markers of Carotid Structure and Function: The Paris Prospective Study III.

  • Gaye B From the INSERM, U970, Paris Cardiovascular Research Center, Department of Epidemiology, France (B.G., S.L., M.C.P., C.G., M.T., P.B., X.J., J.P.E.); Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, France (B.G., S.L., M.C.P., C.G., M.T., P.B., X.J., J.P.E.); APHP, Georges Pompidou European Hospital, Pharmacology Departments, Paris, France (S.L., P.B.); Preventive and Clinical Investigation Center, Paris, France (F.T., B.P.); APHP, Georges Pompidou European Hospital, Cardiology Department, Paris, France (X.J.); and Department of Cardiology, University Hospital of Geneva, Switzerland (H.M.). m.bamba.gaye@gmail.com.
  • Mustafic H From the INSERM, U970, Paris Cardiovascular Research Center, Department of Epidemiology, France (B.G., S.L., M.C.P., C.G., M.T., P.B., X.J., J.P.E.); Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, France (B.G., S.L., M.C.P., C.G., M.T., P.B., X.J., J.P.E.); APHP, Georges Pompidou European Hospital, Pharmacology Departments, Paris, France (S.L., P.B.); Preventive and Clinical Investigation Center, Paris, France (F.T., B.P.); APHP, Georges Pompidou European Hospital, Cardiology Department, Paris, France (X.J.); and Department of Cardiology, University Hospital of Geneva, Switzerland (H.M.).
  • Laurent S From the INSERM, U970, Paris Cardiovascular Research Center, Department of Epidemiology, France (B.G., S.L., M.C.P., C.G., M.T., P.B., X.J., J.P.E.); Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, France (B.G., S.L., M.C.P., C.G., M.T., P.B., X.J., J.P.E.); APHP, Georges Pompidou European Hospital, Pharmacology Departments, Paris, France (S.L., P.B.); Preventive and Clinical Investigation Center, Paris, France (F.T., B.P.); APHP, Georges Pompidou European Hospital, Cardiology Department, Paris, France (X.J.); and Department of Cardiology, University Hospital of Geneva, Switzerland (H.M.).
  • Perier MC From the INSERM, U970, Paris Cardiovascular Research Center, Department of Epidemiology, France (B.G., S.L., M.C.P., C.G., M.T., P.B., X.J., J.P.E.); Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, France (B.G., S.L., M.C.P., C.G., M.T., P.B., X.J., J.P.E.); APHP, Georges Pompidou European Hospital, Pharmacology Departments, Paris, France (S.L., P.B.); Preventive and Clinical Investigation Center, Paris, France (F.T., B.P.); APHP, Georges Pompidou European Hospital, Cardiology Department, Paris, France (X.J.); and Department of Cardiology, University Hospital of Geneva, Switzerland (H.M.).
  • Thomas F From the INSERM, U970, Paris Cardiovascular Research Center, Department of Epidemiology, France (B.G., S.L., M.C.P., C.G., M.T., P.B., X.J., J.P.E.); Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, France (B.G., S.L., M.C.P., C.G., M.T., P.B., X.J., J.P.E.); APHP, Georges Pompidou European Hospital, Pharmacology Departments, Paris, France (S.L., P.B.); Preventive and Clinical Investigation Center, Paris, France (F.T., B.P.); APHP, Georges Pompidou European Hospital, Cardiology Department, Paris, France (X.J.); and Department of Cardiology, University Hospital of Geneva, Switzerland (H.M.).
  • Guibout C From the INSERM, U970, Paris Cardiovascular Research Center, Department of Epidemiology, France (B.G., S.L., M.C.P., C.G., M.T., P.B., X.J., J.P.E.); Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, France (B.G., S.L., M.C.P., C.G., M.T., P.B., X.J., J.P.E.); APHP, Georges Pompidou European Hospital, Pharmacology Departments, Paris, France (S.L., P.B.); Preventive and Clinical Investigation Center, Paris, France (F.T., B.P.); APHP, Georges Pompidou European Hospital, Cardiology Department, Paris, France (X.J.); and Department of Cardiology, University Hospital of Geneva, Switzerland (H.M.).
  • Tafflet M From the INSERM, U970, Paris Cardiovascular Research Center, Department of Epidemiology, France (B.G., S.L., M.C.P., C.G., M.T., P.B., X.J., J.P.E.); Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, France (B.G., S.L., M.C.P., C.G., M.T., P.B., X.J., J.P.E.); APHP, Georges Pompidou European Hospital, Pharmacology Departments, Paris, France (S.L., P.B.); Preventive and Clinical Investigation Center, Paris, France (F.T., B.P.); APHP, Georges Pompidou European Hospital, Cardiology Department, Paris, France (X.J.); and Department of Cardiology, University Hospital of Geneva, Switzerland (H.M.).
  • Pannier B From the INSERM, U970, Paris Cardiovascular Research Center, Department of Epidemiology, France (B.G., S.L., M.C.P., C.G., M.T., P.B., X.J., J.P.E.); Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, France (B.G., S.L., M.C.P., C.G., M.T., P.B., X.J., J.P.E.); APHP, Georges Pompidou European Hospital, Pharmacology Departments, Paris, France (S.L., P.B.); Preventive and Clinical Investigation Center, Paris, France (F.T., B.P.); APHP, Georges Pompidou European Hospital, Cardiology Department, Paris, France (X.J.); and Department of Cardiology, University Hospital of Geneva, Switzerland (H.M.).
  • Boutouyrie P From the INSERM, U970, Paris Cardiovascular Research Center, Department of Epidemiology, France (B.G., S.L., M.C.P., C.G., M.T., P.B., X.J., J.P.E.); Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, France (B.G., S.L., M.C.P., C.G., M.T., P.B., X.J., J.P.E.); APHP, Georges Pompidou European Hospital, Pharmacology Departments, Paris, France (S.L., P.B.); Preventive and Clinical Investigation Center, Paris, France (F.T., B.P.); APHP, Georges Pompidou European Hospital, Cardiology Department, Paris, France (X.J.); and Department of Cardiology, University Hospital of Geneva, Switzerland (H.M.).
  • Jouven X From the INSERM, U970, Paris Cardiovascular Research Center, Department of Epidemiology, France (B.G., S.L., M.C.P., C.G., M.T., P.B., X.J., J.P.E.); Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, France (B.G., S.L., M.C.P., C.G., M.T., P.B., X.J., J.P.E.); APHP, Georges Pompidou European Hospital, Pharmacology Departments, Paris, France (S.L., P.B.); Preventive and Clinical Investigation Center, Paris, France (F.T., B.P.); APHP, Georges Pompidou European Hospital, Cardiology Department, Paris, France (X.J.); and Department of Cardiology, University Hospital of Geneva, Switzerland (H.M.).
  • Empana JP From the INSERM, U970, Paris Cardiovascular Research Center, Department of Epidemiology, France (B.G., S.L., M.C.P., C.G., M.T., P.B., X.J., J.P.E.); Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, France (B.G., S.L., M.C.P., C.G., M.T., P.B., X.J., J.P.E.); APHP, Georges Pompidou European Hospital, Pharmacology Departments, Paris, France (S.L., P.B.); Preventive and Clinical Investigation Center, Paris, France (F.T., B.P.); APHP, Georges Pompidou European Hospital, Cardiology Department, Paris, France (X.J.); and Department of Cardiology, University Hospital of Geneva, Switzerland (H.M.).
Show more…
  • 2016-09-03
Published in:
  • Arteriosclerosis, thrombosis, and vascular biology. - 2016
arterial stiffness
carotid intima–media thickness
epidemiology
plaque
prevention
subclinical disease
Age Factors
Aged
Asymptomatic Diseases
Carotid Arteries
Carotid Artery Diseases
Carotid Intima-Media Thickness
Chi-Square Distribution
Cross-Sectional Studies
Elastic Modulus
Female
Health Status
Humans
Life Style
Logistic Models
Male
Middle Aged
Multivariate Analysis
Odds Ratio
Paris
Plaque, Atherosclerotic
Predictive Value of Tests
Prognosis
Prospective Studies
Risk Factors
Risk Reduction Behavior
Sex Factors
Socioeconomic Factors
Surveys and Questionnaires
Vascular Stiffness
English OBJECTIVE
We hypothesized that subclinical markers of vascular structure and function, which are independent predictors of cardiovascular disease, would be less frequent in subjects with ideal than poor cardiovascular health (CVH) as defined by the American Heart Association (AHA).


APPROACH AND RESULTS
Carotid parameters were measured using high-precision echotracking device in 9155 nonreferred participants attending a health checkup in a large health center in Paris (France) between 2008 and 2012. According to the AHA, participants with 0 to 2, 3 to 4, and 5 to 7 metrics (smoking, physical activity, body mass index, diet, blood glucose and total cholesterol, blood pressure) at the ideal level were categorized as having poor, intermediate, and ideal CVH. Carotid parameters were dichotomized according to their median value, and multivariable logistic regression analysis was performed. Mean age was 59.5 (SD 6.3) years; 39% were females, and ideal CVH was present in 10.11% of the study participants. After adjustment for age, sex, education, and living alone and compared with a poor CVH, an ideal CVH was associated with lower common carotid artery intima-media thickness (odds ratio=1.64; 95% confidence interval 1.40, 1.93), absence of carotid plaques (odds ratio=2.14; 95% confidence interval 1.60, 2.87), lower Young's elastic modulus (odds ratio=2.43; 95% confidence interval 2.07, 2.84), and higher carotid distensibility coefficient (odds ratio=2.90; 95% confidence interval 2.47, 3.41).


CONCLUSIONS
In community subjects aged 50 to 75 years, ideal CVH was associated with substantially less arterial stiffness and thickness. These associations might contribute to the lower risk of cardiovascular diseases in subjects with ideal CVH.
Language
  • English
Open access status
bronze
Identifiers
Persistent URL
https://folia.unifr.ch/global/documents/103377
Statistics
Document views: 19 File downloads:
  • fulltext.pdf: 0